The present invention relates systems and methods for blood processing, and particularly to a three line apheresis system and methods of using the same.
Apheresis is a procedure in which an individual blood component can be separated and collected from whole blood temporarily withdrawn from a subject. Typically, whole blood is withdrawn through a needle inserted into the subjects arm and into a cell separator, such as a centrifugal bowl. Once the whole blood is separated into its various components (e.g., plasma, red blood cells, white blood cells, and platelets), one or more of the components can be removed from the centrifugal bowl. The remaining components are returned to the subject with optional fluid compensation to make up for the volume of the removed component.
One concern with apheresis systems is the amount of extra corporeal volume (ECV), or the amount of whole blood that is outside of the body during the procedure. For the safety of the donor subject and to improve the donor subject's tolerance to the procedure, the extra corporeal volume should be minimized. The limits on the ECV have created a variety of apheresis systems and separation device designs. For example, current apheresis systems typically employ either a continuous flow separation device or discontinuous flow separation device. Continuous flow separation devices do not typically accumulate separated components within the device during separation (although a container may be added external to the separation device). Conversely, blood components typically accumulate within a discontinuous separation device and are later removed or extracted from the separation device.
Another significant difference between continuous and discontinuous separation devices is the number of access ports that each have. In particular, continuous flow separation devices typically have at least 3 access ports (1 input port for the anticoagulated whole blood, and 2 component output ports), whereas discontinuous separation devices only have two ports (an inlet and an outlet).
Apheresis systems utilizing discontinuous separation devices (e.g., a two port centrifuge bowl) draw whole blood from the donor or patient through a conduit into the centrifuge bowl, where component separation takes place. When there is sufficient volume in the bowl, the drawing of fresh blood is stopped, and the unwanted components are returned to the donor or patient through the same conduit intermittently, which creates lag times and increases the overall procedure time. When the return has been completed, whole blood is again drawn from the donor or patient, and a second cycle begins. This batch process continues until the desired amount of component has been collected.
In accordance with embodiments of the present invention, a blood processing system may collect, remove, and exchange blood components. The blood processing system may be a discontinuous system and may include a venous-access device for drawing whole blood from a subject and returning blood components to the subject, and a blood component separation device. The blood component separation device separates the drawn blood into at least a first blood component and a second blood component, and may be configured to send the first blood component to a first blood component bag. The blood component separation device may also have an outlet and may alternate between discharging the first blood component and the second blood component through the outlet. The blood processing system may also have a plurality of lines including, but not limited to, a blood draw line, an anticoagulant line, and a return line. A line specific pump can control the flow through each of these lines.
The blood draw line may be fluidly connected to the venous-access device and configured to transport the drawn whole blood to the blood component separation device. A blood draw pump may control the flow through the blood draw line. The anticoagulant line may be connected to an anticoagulant source, and may introduce anticoagulant into the drawn whole blood, for example, near the venous access device. An anticoagulant pump may control the flow through the anticoagulant line. The return line may fluidly connect the venous-access device and the blood component separation device, and may be used to return the second blood component or compensation fluid to the subject. A return pump may control the flow through the return line. In some embodiments, the return line fluidly connects to the venous-access device at a point between the blood draw pump and the venous-access device.
In accordance with other embodiments, the blood component separation device is a centrifuge bowl, and may separate the drawn blood into a third blood component in addition to the first blood component and the second blood component. The third blood component may be returned to the subject in addition to the second blood component via the return line. The first blood component may be plasma, the second blood component may be red blood cells, and the third blood component may be platelets or other blood cell. Alternatively, the first blood component may be platelets and the third blood component may be plasma.
In accordance with further embodiments, a surge elutriation step may be used to extract the plasma from the bowl using saline solution or other compensation fluid. Additionally, the system may include a valve located on the return line between the blood component separation device and the venous-access device. The valve stops the flow within the return line. During surge elutriation, the blood component separation device may send the first blood component to the first blood component bag. The system may also have a plasma reservoir, located in the return line that holds the plasma.
In accordance with still further embodiments of the present invention, a method of collecting and exchanging blood components is used. The method includes inserting a venous-access device into a subject, and withdrawing blood from the subject. The venous-access device may be connected to a draw line, an anticoagulation line, and a return line. The method withdraws the blood from the subject through the draw line, which is connected to a blood component separation device. A draw line pump controls the flow through the draw line. The method may also introduce anticoagulant into the withdrawn blood through the anticoagulant line. An anticoagulant line pump controls the flow through the anticoagulant line. The amount of blood withdrawn from the subject does not necessarily need to fill the blood component separation device.
Once the withdrawn blood is within the blood component separation device, the method separates the withdrawn blood into a first blood component and a second blood component, and extracts the first blood component from the blood component separation device. The method may then return the second blood component to the subject through the return line that fluidly connects to the venous-access device at a point between the draw line pump and the venous-access device. A return line pump controls the flow through the return line. The blood component separation device may be a centrifuge bowl.
In accordance with other embodiments, the method may also pause the withdrawal of blood while returning the second component to the patient, and repeating some or all of the steps until a target plasma volume is extracted. Additionally, the method may also monitor a pressure within the return line, and adjust the flow of fluid within the return line based on the monitored pressure to maintain the pressure within a desired pressure range. The method may also return a volume of compensation fluid to the subject after blood is drawn from the subject to compensate for the volume of withdrawn blood.
In accordance with still other embodiments, a blood processing system for collecting and exchanging blood components may include a venous-access device for drawing whole blood from a subject and returning blood components to the subject. The system may also have a two-port blood component separation device that separates the drawn blood into a first blood component and a second blood component and sends the first blood component to a first blood component bag. The blood processing system may also have a plurality of lines including, but not limited to, a blood draw line, an anticoagulant line, and a return line. A line specific pump can control the flow through each of these lines.
The blood draw line may be fluidly connected to the venous-access device and configured to transport the drawn whole blood to the blood component separation device. A blood draw pump may control the flow through the blood draw line. The anticoagulant line may be connected to an anticoagulant source, and may introduce anticoagulant into the drawn whole blood, for example, near the venous access device. An anticoagulant pump may control the flow through the anticoagulant line. The return line may fluidly connect the venous-access device and the blood component separation device, and may be used to return the second blood component or compensation fluid to the subject. A return pump may control the flow through the return line. In some embodiments, the return line fluidly connects to the venous-access device at a point between the blood draw pump and the venous-access device. The two-port blood component separation device may be a centrifuge bowl. The first blood component may be plasma and the second blood component may be red blood cells. Alternatively, the first blood component may be platelets and the second blood component may be plasma.
The foregoing features of the invention will be more readily understood by reference to the following detailed description, taken with reference to the accompanying drawings, in which:
Embodiments of the present invention provide a system and method for performing blood apheresis procedures. Specific embodiments offer three-line, single access blood apheresis systems that provide for a decreased overall procedure time, with only limited “dead times,” decreased extra corporeal volume, processing of all drawn blood and minimum exposure of drawn blood to processed returned blood. The method and system may use dedicated lines for withdrawing blood from a subject, introducing anti-coagulant into the drawn blood, and returning unused or processed blood components to the subject. Details of the illustrative embodiments are discussed below.
As shown in
In contrast, as shown in
As the whole blood is being withdrawn from the subject, anticoagulant can be added to the whole blood to prevent the blood from coagulating within the lines or within the blood component separation device 150. To that end, the system may include an anticoagulant line 130 fluidly connected to an anticoagulant source 134 (e.g., a bag of anticoagulant) at one end, and the venous-access device 110 (or the draw line 120) at the other end. An anti-coagulant pump 132, through which the anticoagulant line 130 passes, may control the flow through the anti-coagulant line 130 and the amount of anticoagulant introduced into the whole blood. In some embodiments, the anticoagulant pump 132 operates proportionately to the draw pump 122 to ensure that the proper amount of anticoagulant is added to the whole blood. Although the anticoagulant can be added to the whole blood at any point, it is preferred that the anticoagulant be introduced into the whole blood as close as possible to the venous-access device 110. It is important to note that any of the lines/conduits can include a clamp valve 164 to stop the flow within the line.
Once a desired amount of anti-coagulated whole blood is withdrawn from the subject and contained within the blood component separation device 150, the blood component separation device separates the whole blood into several blood components. For example, the blood component separation device may separate the whole blood into a first, second, third blood component, and, perhaps, a fourth blood component. More specifically, the blood component separation device 150 can separate the whole blood into plasma, platelets, red blood cells, and, perhaps, white blood cells.
As discussed in greater detail below, some embodiments of the blood processing system 100 can include a transfer pump 210 and a dilution/extraction line 160 connected to the plasma bag 158. The transfer pump 210 and dilution/extraction line 160 can be used for a variety of purposes including dilution of the anticoagulated drawn blood being introduced into the blood component separation device. For example, if the user wishes the drawn blood to have a higher plasma content, the system can dilute the withdrawn blood by turning on the transfer pump and introducing plasma from the plasma bag 158 into the withdrawn blood within the draw line 120. Additionally or alternatively, the transfer pump may be used during surge elutriation (discussed in greater detail below) to introduce plasma from the plasma bag 158 into the blood component separation device 150 to extract the platelets (or other blood component).
Although a variety of blood component separation devices 150 can be used to separate the whole blood into blood components, some embodiments of the present invention use a standard Latham type centrifuge, as described in U.S. Pat. No. 3,145,713, which is hereby incorporated by reference. However, other embodiments of the present invention can use other blood component separation devices 150, such as, but not limited to, integral blow-molded centrifuge bowls, as described in U.S. Pat. Nos. 4,983,156 and 4,943,273, which are hereby incorporated by reference.
As shown in
As mentioned above, the blood component separation device 150 separates the whole blood into its constituent components. In particular, as the bowl 12 rotates, centrifugal forces separate the anticoagulated whole blood admitted into the bottom of the bowl into red blood cells (RBC), white blood cells (WBC), platelets and plasma. The number of rotations of the bowl 12 can be selected, for example, within a range of 4,000 to 6,000 rpm, and is typically 4,800 rpm. The blood is separated into different fractions in accordance with the component densities. The higher density component, i.e., RBC 60, is forced to the outer wall 70 of the bowl 12 while the lower density plasma 66 lies nearer the core 72. A buffy coat 61 is formed between the plasma 66 and the RBC 60. The buffy coat 61 is made up of an inner layer of platelets 64, a transitional layer 68 of platelets and WBC and an outer layer of WBC 62. The plasma 66 is the component closest to the outlet port from the separation region and is the first fluid component displaced from the bowl 12 via the outlet port PT2 as additional anticoagulated whole blood enters the bowl 12 through the inlet port PT1.
Once the blood component separation device 150 has separated the blood into the various components, one or more of the components can be removed from the blood component separation device 150. For instance, the plasma may be removed to a plasma bag 158 through line 152 (
In accordance with some embodiments, the system 100 may draw the whole blood, separate it into components, and extract the blood components from a blood component separation device in a discontinuous, batch-like process. For example, the system 100 may draw whole blood from the subject until a specific volume is within the blood component separation device 150. The system 100 may then separate the blood contained within the blood component separation device 150, collect the desired blood component, and return the remaining blood components to the subject. The system 100 may then draw more whole blood from the subject and repeat the process, for example, until a predetermined amount of blood component is collected. In some embodiments, particularly those having only a single outlet on the blood component separation device 150, the blood component separation device 150 can alternate between discharging the first blood component and the second blood component through the same outlet (e.g., PT2 shown in
As shown in
As discussed in greater detail below, the system can have a plurality of valves located through-out the system to control the flow of fluid within the system. For example, the return and draw lines may contain a valve (e.g., valves 281 and 280, respectively) that allow flow through the lines when open and prevent flow when closed. Additionally, each of the lines 152, 154, 222, 232 leading to the storage and waste bags 156, 158, and 220, and the compensation fluid source 230 may have similar valves (e.g., valves 285, 284, 286, and 287, respectively). Additionally, the inlet to the blood component separation device 150 may have valves 282 and 283 that either allow or prevent flow to or from the blood component separation device 150. The valves can be either manual or automatic. In other words, the valve may be manually operated by the user/technician or can be automatically operated, for example, by a controller, when a particular condition is met (e.g., the return line valve 281 closing when air is detected in the line 140, as discussed below).
It should also be noted that any or all of the above described lines can include an air detector to detect the presence of air within the line. For example, the return line 140 may contain an air detector 250. The presence of air bubbles within the lines can be problematic for the operation the system and may also be harmful to the subject if the air bubbles enter the blood stream. Therefore, the air detector 250 may be connected to an interlock that stops the flow within the return line 140 in the event that an air bubble is detected (e.g., by stopping the return pump 142 or closing the valve 281 on the return line 140), thereby preventing the air bubbles from entering the subject. Additionally, in some embodiments, the return line 140 may also include an air trap 270. The air trap 270 may be used to remove any air from the fluid (e.g., blood components or compensation fluid) that is being returned to the subject.
Additionally, as shown in
The system may also include a recirculation pump 210 that recirculates fluid within the system and withdraws blood components from the blood component separation device 150. For example, the recirculation pump 210 can be used to remove the plasma from the blood component separation device 150 or send compensation fluid from the compensation fluid source 230 to the blood component separation device 150 during surge elutriation, which is discussed in greater detail below.
As shown in
Once the anticoagulated whole blood reaches the blood component separation device 150, the blood component separation device separates the blood into the constituent components (e.g., red blood cells, plasma, platelets, and white blood cells) in the layered orientation described above (Step 640). The technician operating the system may then extract one or more of the components (the component extracted is dependent on the purpose of the procedure) (Step 650) and return the remaining blood components to the subject (Step 660). As discussed above, the returned components are returned to the subject via the return line 140 and return pump 142. During the return process, the withdraw line 120 and draw pump 122 can be isolated from the donor (and the return line 140) by closing valve 280 located on the draw line 120. Additionally, during the return process, the anticoagulant pump 132 may be stopped to prevent the flow of anticoagulant. If the target volume of components is harvested/collected (Step 670), the procedure is complete. Otherwise, the system may be used to harvest/collect a second batch of components by repeating steps 620 through 660.
In accordance with other embodiments, and as shown in
It should be noted that the volume of whole blood withdrawn from the subject does not need to equal the volume of the blood component separation device 150. In some embodiments, the volume of withdrawn blood can be less than that of the blood component separation device 150 such that air is still present in the separation device 150. In such embodiments, the subject may have a higher tolerance to the procedure because of the lower extra corporeal volume. Additionally, as discussed above, embodiments of the present invention may pause the draw step when the blood component separation device still contains air (e.g., when the blood component separation device 150 is not full), return compensation fluid to the subject, and then resume the draw to fill the remaining volume within the blood component separation device volume. Again, this minimizes the amount of extra corporeal volume and improves the subjects tolerance to the procedure.
The blood component separation device can then separate the anticoagulated whole blood into the constituent components (Step 640), and one or more of the components may be extracted (Step 650), as discussed above. During this time, the method may, once again, return compensation fluid to the patient (Step 717). Additionally or alternatively, if the components are to be extracted via surge elutriation, the technician may begin to send compensation fluid to the blood component separation device 150. The compensation fluid displaces plasma within the separation device to either the plasma bag 158 or a waste bag 220 (
Some embodiments of the present invention may also include one or more pressure sensors on the return line 140. The pressure sensors (not shown) measure the pressure within the return line 140. The measured pressure may then be used to determine a subject access pressure that corresponds to the pressure at the point of access with the subject. Embodiments of the present invention may then control the flow within the return line 140 based on the subject access pressure. For instance, if the subject access pressure is to high, the return pump 142 can reduce the flow within the return line 140 in order to reduce the subject access pressure and avoid harm to the subject.
Once the system returns the remaining blood components and compensation fluid to the subject, some embodiments of the present invention can determine the amount of blood component (e.g., plasma) extracted and the amount replaced with compensation fluid. In such embodiments, the system may first calculate the bowl mean hematocrit and plasma exchange percentage. The system may then use this information to determine the amount of plasma extracted and the amount of plasma replaced with compensation fluid.
It should be noted that all of the components of the system should be made of suitable materials that are compatible with the substance with which they are in contact. For example, the draw line 120, the return line 140, and lines 152 and 154 should be compatible with blood and blood components. Additionally, the platelet bag 156 and the plasma bag 158 should be compatible with platelets and plasma, respectively. Likewise, the anticoagulant line 130 should be compatible with anticoagulant.
It should be noted that the size and capacity of all of the pumps within the above described embodiments need not be identical. For example, the draw pump 122 may be larger and have a greater capacity than the return pump 142 and the anticoagulant pump 132. Additionally, the flow rates through the respective lines need not be equal. For example, in some embodiments, the flowrate through the withdraw line 120 and draw pump 122 may be greater than the sum of the flowrates through the return pump 142 and the anticoagulant pump 132.
It is important to note that any of the above described embodiments may be used for a variety of apheresis and blood processing procedures. For example, embodiments may be used for red blood cell apheresis, plasma apheresis, platelet apheresis, or a variety of therapeutic applications.
Although the above discussion discloses various exemplary embodiments of the invention, it should be apparent that those skilled in the art can make various modifications that will achieve some of the advantages of the invention without departing from the true scope of the invention.
This application is a divisional of co-pending U.S. patent application Ser. No. 12/102,407, entitled “Three-Line Apheresis System and Method,” filed Apr. 14, 2008, and naming Etienne Pages and Michael Ragusa as inventors, the disclosure of which is incorporated herein, in its entirety, by reference.
Number | Name | Date | Kind |
---|---|---|---|
1025059 | Hatton et al. | Apr 1912 | A |
1611725 | Degerth et al. | Dec 1926 | A |
2087778 | Nelin et al. | Jul 1937 | A |
2661150 | Abbott, Jr. | Dec 1953 | A |
2750107 | More | Jun 1956 | A |
2792172 | Tait | May 1957 | A |
3096283 | Hein | Jul 1963 | A |
3145713 | Latham, Jr. | Aug 1964 | A |
3239136 | Hein | Mar 1966 | A |
3244362 | Hein | Apr 1966 | A |
3409213 | Latham, Jr. | Nov 1968 | A |
3456875 | Hein | Jul 1969 | A |
3489145 | Judson et al. | Jan 1970 | A |
3565330 | Latham, Jr. | Feb 1971 | A |
3655058 | Novak | Apr 1972 | A |
3737096 | Jones et al. | Jun 1973 | A |
3774840 | Boatright | Nov 1973 | A |
3987961 | Sinn et al. | Oct 1976 | A |
4007871 | Jones et al. | Feb 1977 | A |
4010894 | Kellogg et al. | Mar 1977 | A |
4014497 | Spiewok et al. | Mar 1977 | A |
4040965 | Kohlheb | Aug 1977 | A |
4056224 | Lolachi | Nov 1977 | A |
4082217 | Westberg | Apr 1978 | A |
4086924 | Latham, Jr. | May 1978 | A |
4140268 | Lacour | Feb 1979 | A |
4142670 | Ishimaru et al. | Mar 1979 | A |
4151844 | Cullis et al. | May 1979 | A |
4197847 | Djerassi | Apr 1980 | A |
4285464 | Latham, Jr. | Aug 1981 | A |
4300717 | Latham, Jr. | Nov 1981 | A |
4303193 | Latham, Jr. | Dec 1981 | A |
4321921 | Laszczower | Mar 1982 | A |
4387848 | Kellogg et al. | Jun 1983 | A |
4425114 | Schoendorfer et al. | Jan 1984 | A |
4430072 | Kellogg et al. | Feb 1984 | A |
4447221 | Mulzet | May 1984 | A |
4457747 | Tu | Jul 1984 | A |
4464167 | Schoendorfer et al. | Aug 1984 | A |
4466888 | Verkaart | Aug 1984 | A |
4482342 | Lueptow et al. | Nov 1984 | A |
4530691 | Brown | Jul 1985 | A |
4534863 | Bacon et al. | Aug 1985 | A |
4643714 | Brose | Feb 1987 | A |
4647279 | Mulzet et al. | Mar 1987 | A |
4680025 | Kruger et al. | Jul 1987 | A |
4684361 | Feldman et al. | Aug 1987 | A |
4692136 | Feldman et al. | Sep 1987 | A |
4708712 | Mulzet | Nov 1987 | A |
4734089 | Cullis | Mar 1988 | A |
4740202 | Stacey et al. | Apr 1988 | A |
4740313 | Schoendorfer et al. | Apr 1988 | A |
4755300 | Fischel et al. | Jul 1988 | A |
4767396 | Powers | Aug 1988 | A |
4795419 | Yawn et al. | Jan 1989 | A |
4795448 | Stacey et al. | Jan 1989 | A |
4806247 | Schoendorfer et al. | Feb 1989 | A |
4806252 | Brown et al. | Feb 1989 | A |
4808307 | Fischel et al. | Feb 1989 | A |
4850995 | Tie et al. | Jul 1989 | A |
4869812 | Schoendorfer et al. | Sep 1989 | A |
4871462 | Fischel et al. | Oct 1989 | A |
4876013 | Shmidt et al. | Oct 1989 | A |
4889524 | Fell et al. | Dec 1989 | A |
4911833 | Schoendorfer et al. | Mar 1990 | A |
4934995 | Cullis | Jun 1990 | A |
4940543 | Brown et al. | Jul 1990 | A |
4943273 | Pages | Jul 1990 | A |
4968295 | Neumann | Nov 1990 | A |
4983156 | Knelson | Jan 1991 | A |
4983158 | Headley | Jan 1991 | A |
4985153 | Kuroda et al. | Jan 1991 | A |
4994188 | Prince | Feb 1991 | A |
5039401 | Columbus et al. | Aug 1991 | A |
5045048 | Kaleskas et al. | Sep 1991 | A |
5098372 | Jonsson | Mar 1992 | A |
5098373 | Polaschegg | Mar 1992 | A |
5100372 | Headley | Mar 1992 | A |
5100564 | Pall et al. | Mar 1992 | A |
5112298 | Prince et al. | May 1992 | A |
5114396 | Unger et al. | May 1992 | A |
5135667 | Schoendorfer | Aug 1992 | A |
5141486 | Antwiler | Aug 1992 | A |
5147290 | Jonsson | Sep 1992 | A |
5154716 | Bauman et al. | Oct 1992 | A |
5174894 | Ohsawa et al. | Dec 1992 | A |
5194145 | Schoendorfer | Mar 1993 | A |
5217426 | Bacehowski et al. | Jun 1993 | A |
5217427 | Cullis | Jun 1993 | A |
5234403 | Yoda et al. | Aug 1993 | A |
5254248 | Nakamura | Oct 1993 | A |
5273517 | Barone et al. | Dec 1993 | A |
5277701 | Christie et al. | Jan 1994 | A |
5298016 | Gordon | Mar 1994 | A |
5298171 | Biesel | Mar 1994 | A |
5300060 | Nelson | Apr 1994 | A |
5316540 | McMannis et al. | May 1994 | A |
5318512 | Neumann | Jun 1994 | A |
5348533 | Papillon et al. | Sep 1994 | A |
5368542 | McMannis et al. | Nov 1994 | A |
5386734 | Pusinelli | Feb 1995 | A |
5387174 | Rochat | Feb 1995 | A |
5387187 | Fell et al. | Feb 1995 | A |
5403272 | Deniega et al. | Apr 1995 | A |
5405308 | Headley et al. | Apr 1995 | A |
5417650 | Gordon | May 1995 | A |
5431814 | Jorgensen | Jul 1995 | A |
5437598 | Antwiler | Aug 1995 | A |
5437624 | Langley | Aug 1995 | A |
5462667 | Wollinsky et al. | Oct 1995 | A |
5470483 | Bene et al. | Nov 1995 | A |
5484396 | Naficy | Jan 1996 | A |
5494592 | Latham et al. | Feb 1996 | A |
3244363 | Hein | Apr 1996 | A |
5505685 | Antwiler | Apr 1996 | A |
5514070 | Pages | May 1996 | A |
5543062 | Nishimura | Aug 1996 | A |
5551941 | Howell | Sep 1996 | A |
5585007 | Antanavich et al. | Dec 1996 | A |
5607579 | Latham, Jr. et al. | Mar 1997 | A |
5649903 | Deniega et al. | Jul 1997 | A |
5651766 | Kingsley et al. | Jul 1997 | A |
5656163 | Brown | Aug 1997 | A |
5712798 | Langley et al. | Jan 1998 | A |
5728060 | Kingsley et al. | Mar 1998 | A |
5733253 | Headley et al. | Mar 1998 | A |
5733446 | Holm | Mar 1998 | A |
5733545 | Hood, III | Mar 1998 | A |
5738792 | Schoendorfer | Apr 1998 | A |
5762791 | Deniega et al. | Jun 1998 | A |
5779660 | Kingsley et al. | Jul 1998 | A |
5783085 | Fischel | Jul 1998 | A |
5792351 | Wehrle et al. | Aug 1998 | A |
5849203 | Brown et al. | Dec 1998 | A |
5882289 | Sakota et al. | Mar 1999 | A |
5906589 | Gordon et al. | May 1999 | A |
5919125 | Berch | Jul 1999 | A |
5964724 | Rivera et al. | Oct 1999 | A |
5980760 | Min et al. | Nov 1999 | A |
6007725 | Brown | Dec 1999 | A |
6059979 | Brown | May 2000 | A |
6207063 | Brown | Mar 2001 | B1 |
6234989 | Brierton et al. | May 2001 | B1 |
6296602 | Headley | Oct 2001 | B1 |
6464624 | Pages | Oct 2002 | B2 |
6558307 | Headley | May 2003 | B2 |
6652476 | Langley et al. | Nov 2003 | B2 |
6743192 | Sakota et al. | Jun 2004 | B1 |
7115205 | Robinson et al. | Oct 2006 | B2 |
7186231 | Takagi et al. | Mar 2007 | B2 |
7270645 | Langley et al. | Sep 2007 | B2 |
7704454 | Langley et al. | Apr 2010 | B1 |
8702637 | Pages et al. | Apr 2014 | B2 |
20010027156 | Egozy et al. | Oct 2001 | A1 |
20020032398 | Steele et al. | Mar 2002 | A1 |
20020043492 | Bischof | Apr 2002 | A1 |
20030203802 | Westberg et al. | Oct 2003 | A1 |
20040096814 | Langley et al. | May 2004 | A1 |
20040199098 | Pierce et al. | Oct 2004 | A1 |
20050000868 | Weigel et al. | Jan 2005 | A1 |
20050209522 | Tadokoro et al. | Sep 2005 | A1 |
20060058167 | Ragusa et al. | Mar 2006 | A1 |
20060155236 | Gara et al. | Jul 2006 | A1 |
Number | Date | Country |
---|---|---|
0 128 683 | Dec 1984 | EP |
0 171 749 | Feb 1986 | EP |
0 208 061 | Jan 1987 | EP |
0 257 755 | Mar 1988 | EP |
0 578 086 | Jan 1994 | EP |
0 619 145 | Oct 1994 | EP |
0 664 159 | Jul 1995 | EP |
0 799 645 | Oct 1997 | EP |
0 885 619 | Dec 1998 | EP |
1 057 534 | Dec 2000 | EP |
1 374 927 | Jan 2004 | EP |
2 258 898 | Aug 1975 | FR |
2 047 110 | Nov 1980 | GB |
59-006952 | Jan 1984 | JP |
59-069166 | Apr 1984 | JP |
07-075746 | Mar 1995 | JP |
08-131539 | May 1996 | JP |
09-192215 | Jul 1997 | JP |
11-504836 | May 1999 | JP |
2002-291872 | Oct 2002 | JP |
2003-516175 | May 2003 | JP |
2005-110748 | Apr 2005 | JP |
2008-506424 | Mar 2008 | JP |
660718 | May 1979 | SU |
762982 | Sep 1980 | SU |
1146098 | Mar 1985 | SU |
WO 8502561 | Jun 1985 | WO |
WO 9000059 | Jan 1990 | WO |
WO 9007383 | Jul 1990 | WO |
WO 9406535 | Mar 1994 | WO |
WO 9611747 | Apr 1996 | WO |
WO 9633023 | Oct 1996 | WO |
WO 9640322 | Dec 1996 | WO |
WO 0128621 | Apr 2001 | WO |
WO 2007041716 | Apr 2007 | WO |
Entry |
---|
Alessandro Germano, Authorized officer European Patent Office, International Search Report and Written Opinion of the International Searching Authority—Application No. PCT/US2009/040166, dated Oct. 1, 2009 (15 pages). |
The State Intellectual Property Office of the People's Republic of China, First Official Action—Application No. 200980120814.6, dated Jan. 4, 2013 (6 pages). |
The State Intellectual Property Office of the People's Republic of China, First Official Action (Notification of the First Office Action)—Application No. 200980120814.6, dated Jan. 4, 2013 (6 pages) [English Translation]. |
Hu, Yating, The State Intellectual Property Office of the People's Republic of China, Second Official Action—Application No. 200980120814.6, dated Nov. 18, 2013 (7 pages). |
Hu, Yating, The State Intellectual Property Office of the People's Republic of China, Second Official Action (Notification of the Second Office Action)—Application No. 200980120814.6, dated Nov. 18, 2013 (8 pages) [English Translation]. |
Japanese Patent Office, First Official Action—Application No. 2011-504,195, dated May 28, 2013 (3 pages). |
Japanese Patent Office, First Official Action—Application No. 2011-504,195, dated May 28, 2013 (3 pages) [English Translation]. |
Japanese Patent Office, Final Official Action—Application No. 2011-504,195, dated Oct. 2, 2013 (2 pages). |
Japanese Patent Office, Final Official Action (Final Decision for Rejection)—Application No. 2011-504,195, dated Oct. 2, 2013 (2 pages) [English Translation]. |
Japanese Patent Office, First Official Action—Application No. 2014-021910, dated Dec. 19, 2014 (2 pages). |
Japanese Patent Office, First Official Action—Application No. 2014-021910, dated Dec. 19, 2014 (2 pages) [English Translation]. |
Number | Date | Country | |
---|---|---|---|
20140100506 A1 | Apr 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12102407 | Apr 2008 | US |
Child | 14101899 | US |